Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03530293 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT03530293 is a Phase 2 study that was terminated before completion, run by Neurocrine Biosciences. The registered enrollment target is 81 participants.
The verdict
NCT03530293, a Phase 2 study, was terminated before completion, sponsored by Neurocrine Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS.
Interventions
- DRUG Placebo oral capsule
- DRUG Valbenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2018-04-17 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03530293
The ClinicalTrials.gov registry entry for NCT03530293 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03530293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03530293 about?
NCT03530293 is a clinical study titled "Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome". This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS.
What is the current status of trial NCT03530293?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2018-04-17. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT03530293?
The interventions under investigation include: Placebo oral capsule (DRUG), Valbenazine (DRUG).
Who is sponsoring clinical trial NCT03530293?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.